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Abstract The analysis of volatile organic compounds
(VOC) as biomarkers of cancer is both promising and
challenging. In this pilot study, we used an untargeted
approach to compare volatile metabolomic signatures of
melanoma and matched control non-neoplastic skin from
the same patient. VOC from fresh (non-fixed) biopsied
tissue were collected using the headspace solid phase micro
extraction method (HS SPME) and analyzed by gas chro-
matography and mass spectrometry (GCMS). We applied
the XCMS analysis platform and MetaboAnalyst software
to reveal many differentially expressed metabolic features.
Our analysis revealed increased levels of lauric acid
(C12:0) and palmitic acid (C16:0) in melanoma. The
identity of these compounds was confirmed by comparison
with chemical standards. Increased levels of these fatty
acids are likely to be a consequence of up-regulated de
novo lipid synthesis, a known characteristic of cancer.
Increased oxidative stress is likely to cause an additional
increase in lauric acid. Implementation of this study design
on larger number of cases will be necessary for the future
metabolomics biomarker discovery applications.
Keywords Volatile organic compounds  Skin cancer 
Metabolites  GCMS  Palmitic acid
1 Introduction
Cancer, as the leading cause of death worldwide, is projected
to increase from 7.9 to 11.5 million, for a period from 2007 to
2030 (Thun et al. 2010). Early detection of cancer greatly
increases the chances of successful treatment. If detected
early (when confined to the primary site) the melanoma
5 year survival rate is about 98.2 % (Howlader et al. 2012).
Unfortunately, the majority of melanoma cases are not
detected in this early time window. Given its origin as a
pigmented lesion on the skin, melanoma presents a unique
opportunity for early detection. However detecting early
melanoma in sun-damaged skin is not always an easy task, as
the lesions may be masked by ephelides (freckles), seborr-
heic keratosis, pigmented actinic keratoses, lentigines or
nevi (Moller et al. 2009). There have been several anecdotal
reports of canine detection of melanoma (Williams and
Pembroke 1989; Church and Williams 2001). Many studies
have demonstrated the extreme olfactory ability of dogs to
detect and distinguish cancer from non-cancer (Willis et al.
2004; McCulloch et al. 2006; Horvath et al. 2008; Sonoda
et al. 2012). These observations suggest that the headspace
over melanoma contains volatile molecules. The idea to use
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volatile organic compounds (VOC) or metabolites to aid in
early detection of skin diseases and melanoma is not new
(D’Amico et al. 2008; Gallagher et al. 2008; Abaffy et al.
2010). It has been demonstrated that metabolic changes due
to a cancer process are reflected in the secretion products
from exocrine glands and of volatiles released by the skin.
Skin volatile compounds and their modifications caused by
environmental factors have been studied using sorbtive tape
extraction and in vivo sampling methods (Sisalli et al. 2006;
Bicchi et al. 2007; Sgorbini et al. 2010).
In many different cancers, breath analysis was used to
determine which volatile compounds-metabolites can serve
as potential biomarkers. Phillips et al. studied volatile
metabolites in lung and breast cancer patients (Phillips
1997; Phillips et al. 1999, 2003, 2010). Chen et al. (2007)
used HS SPME GCMS method to extract volatile organic
metabolites from breaths of lung cancer patients. In addi-
tion many other cancers have been investigated using
chemical analysis of exhaled breath (ovarian, colon, pros-
tate, liver and stomach cancers) (Peng et al. 2010; Meloni
et al. 1999; Ligor et al. 2007; Sonoda et al. 2012). Using an
animal model approach, Matsumura et al. showed that
urine volatile metabolic signature could distinguish tumor-
bearing mice from control animals (Matsumura et al.
2010). In addition, it has been demonstrated that the urine
volatile metabolomic profile from leukemia, colorectal
cancer and lymphoma can differentiate cancer patients
from healthy individuals (Silva et al. 2011). Thus, VOC/
metabolite analysis of skin as well as breath and urine can
be a novel diagnostic approach to detect cancer.
Recent study tested the hypothesis that malignant mel-
anoma tissue forms a unique volatile signature that is dif-
ferent than skin and nevi (non-neoplastic and benign
lesional tissue) and demonstrated proof of principle that
malignant melanoma tissue has a volatile profile distinct
from healthy, non-neoplastic skin and nevi (Abaffy et al.
2010). In that study, mass spectra from a given sample
were compared to the NIST reference library and the
metabolites were identified if they had C60 % similarity.
The major limitation of that study was the control tissue,
which could not be matched for sex, age, environmental
and other potential confounding factors. The aim of this
preliminary study was to directly compare volatile meta-
bolic profiles of melanoma (M) and non-neoplastic (non-
melanoma, NM) skin using matched control, healthy,
adjacent skin from the same patient, isolated and analyzed
on the same day. We applied an untargeted approach, as
this represents an efficient tool for early detection of dis-
ease (Ackermann et al. 2006; Sreekumar et al. 2009). We
focused on validation of this novel approach, including
spectra processing and statistical analysis. Due to the small
sample size, this pilot study does not seek to identify
biomarkers of melanoma. However, we did annotate
several metabolic ‘‘features’’ that were significantly dif-
ferent between malignant melanoma and skin. Significant
metabolites present in the melanoma were identified as
fatty acids and confirmed with standards. Their presence
may indicate increased cellular oxidative stress (C12:0)
and increased cellular proliferation (C16:0 and C12:0)
(Lindahl 1992; Rahman et al. 2002; DeBerardinis et al.
2008; Marchitti et al. 2008).
2 Materials and methods
2.1 Sample preparation and volatile collection
We obtained ethics approval from the Institutional Review
Board (IRB). Biopsy samples were collected from subjects
recruited in accordance with the approved IRB protocol
(No. 2006117) after a written consent form was signed.
Samples were subjected to HS SPME volatile collection
and GCMS analysis as described previously (Abaffy et al.
2010, 2011). A total of ten patients were recruited: five
with melanoma lesions (Table 1) and five with non-mela-
noma (benign lesions) (Table 2). Two tissue biopsies were
performed on each patient with a 2 mm punch biopsy
device, one from the lesion (melanoma or non-melanoma
lesion) and the other from adjacent healthy skin from the
same patient. The biopsy sample was placed in a vial
(Agilent, No. 5182-0715, 1.5 mL with 0.3 mL polyspring
insert, National Scientific, C4010-630, insert diameter
3 mm) and capped with a Teflon coated silicon septum,
which sealed the air within the insert from the vial and the
external environment. Tissue sample was placed at the
bottom of the insert leaving approximately 15 mm of space
above the tissue. The sample was kept on ice for a maxi-
mum of 2 h after biopsy and before the HS SPME volatile
collection. Upon insertion of the SPME fiber, volatile
compounds partition to the gaseous phase as well as to the
SPME fiber coating. The extractive portion of the SPME
fiber was 10 mm in length. It was completely exposed to
the headspace above the tissue during the extraction period
without directly contacting the sample. Under these cir-
cumstances, volatile compounds prefer to accumulate in
the headspace, resulting in substantial loss of sensitivity
when the headspace volume is too large. In order to min-
imize the headspace and to achieve higher sensitivity of
headspace extraction, we placed a 0.3 mL insert into the
vial. We collected volatile compounds using HS SPME
device with 0.65 lm PDMS-DVB fiber for 1 h at room
temperature. The manual HS SPME holder was inserted
into injector of the GC (splitless mode) and volatiles from
fiber desorbed (at 220 C for 1 min). The SPME fiber was
conditioned at 250 C under a purified stream of helium
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prior to first use according to manufacturer’s instructions.
Blank fiber was directly injected each day before the
analysis. Only two samples (melanoma or non-melanoma
and control healthy skin) were analyzed per day. We
analyzed 20 tissues (five melanoma ?5 matching skin and
five non-melanoma ?5 matching skin), and ten air sam-
ples. Analysis of air samples (volatile collection from the
empty vial) was done in the same way as melanoma and
skin samples.
2.2 GCMS analysis
GSMS analysis was performed using an HP 6890 gas
chromatograph and Agilent 5973 quadrupole mass spec-
trometer operating in the electron impact (EI) mode. The
filament off time was 0.1 min. This was used to reduce the
signal from gases N2 and CO2 that are injected via the
SPME fiber. Before each analysis set the instrument was
tuned via the autotune function of the instrument. Our
Table 1 Demographics, diagnosis and histology analysis (H&E staining) of 5 matched melanoma cases
Case M-1 Case M-2 Case M-3 Case M-4 Case M-5
Sex M M M M F
Race White White Hispanic dark skin White Hispanic dark
skin
Age 49 73 35 75 38







Localization Right forearm Right temple Right foot Scalp Back
Tissue/lesion Intact Previously shaved Intact Previously shaved Intact
Breslow
thickness
0.98 mm 0.75 mm 2.2 mm 0.67 mm 5 mm
Clark level,
TNM stage





Malignant melanoma Melanoma in situ Acral lentigenous
melanoma







The site of punch biopsy of melanoma (indicated with ) and of adjacent skin are indicated with white circle. Unfortunately, we did not obtain
the macroscopic picture for case M-5
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program was: 40 C for 2 min followed by 6 C/min ramp
to 270 C and hold for 5 min. Helium carrier gas flow was
set at 0.7 mL/min. Agilent 5973 mass spectrometer was
used in the full scan mode at a mass range of 30–300 amu.
Column used: DB-5MS, model J&W 128-5522,
25 m 9 0.2 mm I.D. 9 0.33 lm film. EI ionization used
was 70 eV. DB-5MS is a phenyl arylene polymer equiva-
lent to a 5 %-phenyl-methylpolysiloxane (DB-5). Repro-
ducibility of the method was tested using lauric acid as a
standard. The reproducibility or precision was determined
as % of relative standard deviation (%RSD) and was 8.6 %
(n = 7).
2.3 Chemometric data analysis
After GCMS analysis, raw data were converted to netCDF
files using MASSTransit software (by Palisade-Scientific
Instrument Services, Ringoes, NJ, USA). GCMS spectra
Table 2 Demographic, diagnosis and histology analysis of five non-melanoma cases
Case NM-1 Case NM-2 Case NM-3 Case NM-4 Case NM-5
Sex M M M M F
Race White White White White White
Age 50 83 64 34 77
Initial diagnosis Melanoma Lentigo maligna
melanoma
Melanoma in situ Melanoma in situ Melanoma in situ
Localization Vertex of the scalp Left temple Left cheek Right posterior
auricular
Forehead
Tissue/lesion Previously shaved Intact Previously shaved Previously shaved Previously shaved
Breslow
thickness
0.82 mm 1.1 mm – – –
Clark level,
TNM stage














The site of punch biopsy of non-melanoma (indicated with ) and of nearby skin are indicated with white circle. The macroscopic picture for
Case NM-5 is missing, because initial diagnosis was done in the primary care office
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processing were carried out using freely available XCMS
software (online version 1.21.01, The Scripps Center for
Metabolomics, La Jolla, CA, USA) (Smith et al. 2006)
using the default parameters for GC Single Quadruple
[general: GC/single quad MS (matched Filter), GC-EI,
single quadruple MS, retention time (RT) format: minutes,
polarity: positive, feature detection: matched Filter, step:
0.25, FWHM: 3, RT correction: method: peak groups, non-
linear/linear alignment: loess, extra: 1, missing: 1 Align-
ment: mzwid: 0.25, minfrac: 0.5, bw: 10). GCMS spectra
processing included: filtering and identifying peaks,
matching peaks across samples, peak RT alignment and
arranging peaks into peak intensity table for further sta-
tistical analysis]. Thus, all chromatograms were simulta-
neously analyzed with identical settings. The processed
data were uploaded into freely available MetaboAnalyst
software for statistical analysis (www.metaboanalyst.ca)
(Xia et al. 2009; Xia and Wishart 2011). The total ion count
(TIC) for each chromatogram varied between the samples,
as seen in Supplementary Table ST1. The source of this
variation is likely to be biological, (different skin type and
localization on the body). In addition, some of the variation
may come from differences in the instrumental conditions.
Although analytical conditions were controlled, samples
were collected and analyzed over several months and thus
slight changes in the SPME fiber properties over time may
have contributed to the variation seen in TIC. On the other
hand, the change in TIC in each pair sample (melanoma vs.
skin and non-melanoma vs. skin) was negligible and we
used pairwise analysis throughout our manuscript to
investigate differences between these two groups. The
intensity signal of each metabolic feature is expressed in
relative terms, as a percentage of TIC/intensity signals of
the feature in each sample. For the untargeted approach, the
entire chromatogram (all m/z values) is equally important.
In a complex sample like skin, accurate compound iden-
tification is challenging. Some peaks may contain mixtures
of metabolites that are co-eluting, so the individual MS
scans of their peaks are not pure spectra of either metab-
olite, thus making it difficult to achieve high spectral
matching with the reference library. Some chromato-
graphic peaks with lower abundance are difficult to dis-
tinguish from the noise. To overcome these problems we
used a chemometric approach, meaning that the chemical
compounds were not annotated before the statistical anal-
ysis, only their mass spectra (mass to charge ratio,
m/z value) and the RT of the chromatographic peak (RT)
were recorded as a metabolic ‘‘feature’’. Since individual
chemical compounds give rise to more than one fragment
ion upon ionization, these ion-features, generated by
XCMS, were grouped together using the CAMERA algo-
rithm (Smith et al. 2006; Kuhl et al. 2012). Annotation of a
given mass spectrum was assigned only after a metabolic
‘‘feature’’ showed a statistically significant differential
profile using Student t-tests and fold change analysis. The
Chemical Analysis Working Group of the Metabolomics
Standards Initiative (MSI, http://msi-workgroupssource
forge.net) (Sumner et al. 2007) has defined four different
levels of metabolites identification confidence. The identity
of lauric and palmitic acid was confirmed with level 1
confidence with Sigma Aldrich W261408 and P0500
standards, respectively. In addition, retention indices were
used in combination with mass spectral analysis (similarity
search) to help with annotation of four additional volatiles.
For these purposes a Restek standard (Restek, Bellefonte,
PA, USA) containing 50 lg/mL of n-alkane mix (Cat. No.
31633) was run using the same instrument parameters and
experimental conditions as for melanoma samples. RTs of
each hydrocarbon standard eluted was recorded and the RI
calculated as described in (Lucero et al. 2009).
3 Results
Our study design is presented in Fig. 1 and a detailed
description of each step is given in ‘‘Materials and meth-
ods’’ section. Here, we describe the comparison of volatile
metabolomic signatures from three groups: air versus skin
samples, melanoma versus matching skin (Table 1) and
non-melanoma versus matching skin (Table 2).
3.1 Comparison of skin and air samples
We analyzed ten air against ten skin samples (five from
melanoma cases and five from non-melanoma cases). Vol-
atile collection in these samples was not matched, meaning
samples from these two groups were not collected at the same
time. Chromatographic data were processed as described in
‘‘Materials and methods’’ section. The results from XCMS
analysis, a mirror plot, summarizing most significant up-
regulated features-ions whose intensities were altered
between skin and air samples using thresholds of p B 0.01
and fold change C1.5 is presented in Fig. 2a. A total of 77
metabolic features were identified. The table of absolute
intensity peaks from XCMS was transformed to the relative
intensities table in each particular sample and imported into
MetaboAnalyst for the statistical analysis (matrix of 20
samples and 400 features). Data were normalized using the
autoscaling option. Three hundred and nine features with
C1.5 fold change in relative expression value were identified
when air and skin group was compared. There were 158
features identified as significant by paired t-tests with p value
B0.05. Data were clearly separated in two groups using
unsupervised Principal Component Analysis (PCA) analysis
(Supplementary Fig. 1). In addition, we performed a partial
least squares-discriminant analysis (PLS-DA). Figure 2b
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shows the representative points of the air and skin samples
mapped in space spanned by the first two components in the
PLS-DA. There is a clear separation between air (grey cir-
cles) and skin (black circles) group. The PLS-DA plot
suggests that 23.2 % of the variance is the difference
between air and biopsy tissue. It does appear that the dif-
ference between air and biopsy tissue does not capture the
majority of the variance in the data. However, all of the
Fig. 1 Study design. a Tissue sampling. b Collection of volatile
compounds using head space solid phase micro-extraction method
(HS SPME). c Gas chromatography–mass spectrometry analysis
(GCMS). d Data processing includes alignments of all chromato-
grams, baseline correction, filtering and statistical analysis. e Metab-
olite annotation. f Histology analysis, pathology status confirmation
Fig. 2 XCMS analysis. a Mirror plot. Mirror plot showing up-
regulated metabolic features-ions (green circles) altered between skin
and air samples. Note, that there are no down-regulated features. The
size of each circle corresponds to the (log) fold change of the feature
(the average difference in relative intensity of the peak between
sample groups). Thus, larger circles correspond to peaks with greater
fold change. Also, intensity of the color is used to represent p value
with brighter circles having lower p-values, i.e. higher significant
difference (Tautenhahn et al. 2012). b PLS DA score plot. A clear
separation between the air (grey circles) and the skin (black circles)
group (% of variance for each principal component is presented too)
(Color figure online)
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remaining variance is not necessarily independent of this
difference. For example, we have only shown the two PLS
components which best achieve a compromise between two
aims, namely, describing or capturing the explanatory vari-
ables and predicting the response or tissue class. There may
be other PLS components that explain the variance which
separates the air and biopsy data sets, but may be less pre-
dictively useful. Also, PLS-DA likely does not capture all of
the variability between air and biopsy tissue. It is a technique
which tries to find the best lower dimensional projections of
the data based on certain assumptions about the data (nor-
mality, linearity). It is likely that such complex data does not
meet these assumptions, so PLS-DA is likely to only capture
a portion of the overall variability.
3.2 Comparison of melanoma cases versus matching
skin controls
First, we report the analysis of volatile metabolic profiles
from five confirmed melanoma patients using fresh skin
tissue biopsy from melanoma lesion and from uninvolved
adjacent skin from the same patient. Detailed demographic
data, diagnosis, localization, punch biopsy sites, final
pathology report and histology pictures are presented in
Table 1. Melanoma tissues from cases M-1, M-3 and M-5
were not subjected to shave biopsy prior to punch biopsy
for the current study (intact). Pre-surgical diagnoses in
these cases were obtained from other lesions on the skin
and confirmed histologically after volatile analysis. We
obtained paired melanoma and uninvolved adjacent skin
samples and analyzed them on the same day. We analyzed
results using relative intensity values. The relative intensity
signal was defined as the absolute signal intensity value
divided by the TIC from each sample and imported into
MetaboAnalyst software. This approach normalizes the
TIC from each collection to control for variations in col-
lection efficiency with the SPME fiber and the GC column.
Previous studies reporting GCMS analysis have listed a
huge number of features, but identification of only a small
number of compounds (Bottcher et al. 2008). Thus, an
additional step to categorize these features into smaller
feature groups (FG) was applied. Each FG contains fea-
tures that are likely related to the same compound based on
RT, peak shape and intensity correlations (Kuhl et al. 2012;
Tautenhahn et al. 2012). Our 487 features were thus clas-
sified into 105 FG. In MetaboAnalyst, data were normal-
ized using the autoscaling option. Six significant features,
assigned to six FG, were identified by t test assuming equal
variances and are listed in the Supplementary Fig. S2a.
Important features identified by fold change (C1.5X)
analysis were presented in Supplementary Fig. S2b.
3.3 Annotation of significant feature groups
Next, we wanted to annotate these six FG (FG: 23, 36, 54,
56, 60 and 79, Table 3). We manually analyzed peaks at
the given RT and compared these mass spectra with the
library hits from NIST database. In addition, retention
index was calculated, as described in ‘‘Materials and
methods’’ section, to help in annotation of mass spectra.
The annotations of the FG together with their retention
indices are listed in Table 3. The annotated compounds
found to be significantly increased in melanoma group
were 2-ethylhexyl-4-methoxycinnamate, 1-eicosene; lau-
ric; palmitic; and myristic acid. Only one compound, tol-
uene, was identified as decreased in melanoma relative to



















36 M56T37 37.23 2,234 2,112 1,997 846 1-Eicosene 1
54 M60T26, M73T26, M60T26 26.35 1,581 1,565 1,570 916 Dodecanoic or
lauric acid
1
56 M55T34, M57T34, M60T34,
M73T34, M256T34
33.50 2,010 1,964 1,968 864 Hexadecanoic or
palmitic acid
1
60 M91T6, M92T6 5.80 348 749 758* 899 Toluene –
79 M60T30 30.08 1,805 1,763 1,769 871 Tetradecanoic or
myristic acid
1
The last column indicates the direction of change in melanoma group
* RI value for toluene from NIST library, using a capillary, standard non-polar, DB-1 column
Bold entries indicate statistical significance (p \ 0.05)
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skin. Since the medication used by our melanoma patients
was not uniform Supplementary Table ST2) and because
these compounds were identified relative to the paired
healthy skin control biopsy from the same patient, we are
confident that none of the volatile compounds listed in the
Table 3 are secondary metabolites of medication. Of these
compounds, cinnamaldehydes are known to be present in
cosmetic products and also in our skin (Gallagher et al.
2008). At this point, it is difficult to be certain about its
origin in our melanoma samples.
3.4 Comparison of five non-melanoma cases
versus matching skin controls
We also analyzed volatile profiles of five non-melanoma
cases, which had been initially diagnosed as melanoma
based on previous shave-biopsy histological analysis. After
diagnosis based on the original shave-biopsy, patients were
scheduled for surgical excision of the lesion. In these five
surgical excision biopsy samples the absence of residual
melanoma was confirmed histologically (Table 2). XCMS
analysis of the raw data was performed and there were no
dysregulated features detected between non-melanoma and
matching skin, using 1.2 fold change threshold and using
p value significant threshold of 0.09 and highly significant
threshold of 0.05. It is important to mention that the
inability to find differentially expressed features between
non-melanoma and adjacent control matched skin
(Table 2) is in agreement with histologic analysis which
did not find neoplastic changes (consistent with the absence
of melanoma).
4 Discussion
Our primary interest, due to a small sample size, was to
present the improved methodological control for the
potential confounding factors: non-neoplastic, adjacent
skin from the same patient. We believe that this is a sig-
nificant improvement in study design. Following stringent
criteria for compound identification based on proposed
minimum reporting standards for chemical analysis from
the MSI (Sumner et al. 2007), we annotated volatile
compounds based on their spectral similarity with library
match and retention index. Six FG with statistically sig-
nificant differences between histologically confirmed mel-
anoma and adjacent non-neoplastic skin obtained from the
same patient during a single surgical session were listed in
Table 3. The identities of lauric and palmitic acid were
confirmed at level 1 confidence using chemical standards
and according to the MSI criteria. Human Metabolome
Database search (www.hmdb.ca) lists palmitic acid
(HMDB00220) as one of the most common saturated fatty
acids found in animals and plants, with detectable con-
centrations in human serum, cerebrospinal fluid and urine.
Lauric acid (HMDB00638) was also found in human
serum, cerebrospinal fluid and urine. Our analysis indicates
significantly increased levels in melanoma relative to
adjacent uninvolved skin.
VOC released from skin form body odor and convey
important information about our metabolism (Bernier et al.
2000; Gallagher et al. 2008). It is well known that volatile
profile of human skin changes with age, nutritional status
and environmental factors. At older age, decreased hor-
monal levels result in decreased secretion from apocrine
and sebaceous glands and ultimately lead to change in
volatile profile and skin odor (Zouboulis et al. 2007; Chen
et al. 2007). In addition to the topographic and age related
variations in the lipid composition of human skin, varia-
tions in lipids and their secondary metabolites due to
cancerous process are also present (Abaffy et al. 2010).
Thus, our adjacent non-neoplastic skin is the best choice of
control.
What about nevi? A differential volatile profile in nevi
when compared to melanoma has been shown,, however
these samples were not matched (Abaffy et al. 2010).
Increased number of nevi and extent of freckling is an
important risk factor for melanoma (Tucker 2009). Results
from clinical and histological data indicate that about 25 %
of melanoma arise from or are associated with pre-existing
nevus (Marks et al. 1990; Tsao et al. 2003). Nevi are
considered a benign tumor of melanocytes that have
oncogene-induced senescent phenotype (non-proliferating
cells) (Michaloglou et al. 2005). This is a barrier to
malignant transformation. However, it has also been shown
that some markers of senescence are expressed in mela-
noma (Reed et al. 1995; Tran et al. 2012). Together, these
data call for caution when comparing melanoma and nevi,
and add an additional level of complexity if one was to
consider nevi as a proper control.
The question about the biochemical origin of these
metabolites arises from our results. It is known that during
early stages of melanoma progression, innate and adaptive
immune cells are recruited to the tumor site (e.g. macro-
phages). In addition, structural components of extracellular
matrix including collagens, elastins and soluble factors like
cytokines, chemokines and polypeptide growth factors are
released either from neoplastic or non-neoplastic cells. It is
known that tumor associated macrophages release matrix
metalloproteinase (MMP) and elastase and are thus
actively involved in breaking and remodeling of extracel-
lular matrix (Schmid and Varner 2010). Two possible not
mutually exclusive explanations related to the origin of
palmitic acid exist: (1) the necessity for the increased lipid
synthesis due to cell growth and proliferation in cancer and
(2) the endogenous presence of C16 in the skin is more
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prominent in melanoma skin lesion due to changes in
Stratum Corneum and melanoma cell microenvironment.
First, increased de novo fatty acid (FA) biosynthesis is a
very important metabolic alteration associated with cell
proliferation and cancer (DeBerardinis et al. 2008). Fatty
acid synthase over-expression in melanoma has been cor-
related with Breslow thickness and overall poor survival
(Innocenzi et al. 2003; Kapur et al. 2005; Byrum et al.
2011). It is highly likely that our increased pool of palmitic
acid serve as a building block for plasmalogenes synthesis
(Fig. 3). Plasmalogens are phospholipids with vinyl ether
linkage (Han and Gross 2005). As a general rule, the
amounts of the plasmalogens in the plasma membrane do
not exceed more than 1 %. However, if they amount
for [4 % of total phospholipids it correlates with neo-
plastic transformation (Mangold and Paltauf 1983; Smith
et al. 2008). High temperature GCMS have been used to
study skin surface lipids and predominant fatty acid iden-
tified were hexadecenoic or sapienic acid (C16:1) and
hexadecanoic or palmitic acid (C16:0) (Michael-Jubeli
et al. 2011). This poses a question as to whether or not a
disruption of Stratum Corneum integrity due to melanoma
results in increased palmitic acid volatile profile. If so, it
could represent an additional and/or alternative source of
increased palmitic acid pool.
Our analysis also reveals increased lauric acid in mel-
anoma. This medium-chain fatty acid can originate from
increased de novo fatty acids biosynthesis present in can-
cer, but it can also be a product of increased aldehyde
dehydrogenase activity (ALDH) reported to be present in
many cancers (Lindahl 1992). Elegant work by Boonya-
ratanakornkit et al. (2010) showed that melanoma initiating
cells expressing high ALDH activity develop xenograft
melanomas with high proliferative and self-renewal ability.
Increased lipid peroxidation can also be an indirect source
of aldehydes present in cancer cell. Aldehydes derived
from the lipid peroxidation are oxidized to carboxylic acids
by ALDH, and this is in most cases considered as a
detoxification process (Vasiliou et al. 2000). Thus, lauric
acid present in our melanoma group suggests that it may be
due to increased plasma membrane lipid peroxidation.
The only volatile compound found to be decreased in
the melanoma group is toluene. It is tempting to speculate
that it is an environmental contaminant and not an
endogenous metabolite; however, a few studies based on
much larger sample size have also identified toluene as a
discriminant compound identified as decreased in the
breath of lung cancer non-smoker patients (Rudnicka et al.
2012).
5 Conclusions
The use of volatile organic metabolites as biomarkers of
cancer is a new frontier in cancer research. Our analysis
revealed increased levels of lauric acid and palmitic acid in
melanoma. While these results are encouraging, a larger
effort will be required to fully validate these findings and
Fig. 3 Palmitic and lauric acid
as major volatiles implicated in
metabolic changes of melanoma
cell proliferation. SC stratum
corneum, K keratinocyte,
M melanoma cell, ACC acyl
CoA carboxylase, FASN fatty
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assign these volatiles as biomarkers of melanoma.
Increased levels of these fatty acids are likely to be a
consequence of up-regulated de novo lipid synthesis and
increased oxidative stress. We believe that our approach of
collecting volatile organic metabolites in the headspace
above the cancer tissue has a future potential to become a
non-invasive in situ collection (without a biopsy). This will
enormously speed up biomarkers research discovery and
validation. Implementation of this study design on larger
number of cases will be necessary for the future meta-
bolomics biomarker discovery applications.
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